Research

Mixed

Berberine supplementation reduces atherosclerotic plaque area and inflammatory markers in animal models of cardiovascular disease.

Berberine shows promise in reducing atherosclerosis in animal studies by lowering inflammation and oxidative stress. While human trials are limited, it may be a supportive supplement for cardiovascular health, particularly for those with metabolic issues. Consult a doctor before use, especially if taking other medications.

ModerateSupportsMEDIUM confidence
BBR (150 mg/kg/d, p.o., 12wk) obviously treatment reduced the atherosclerotic plaque area and displayed suppression of inflammatory and oxidative markers [106]. Specifically, BBR diminished the serum levels of IL-1β and TNFα, and decreased the expression of ICAM-1, iNOS, and IL-6 in the aorta.
Xiaojun Feng et al. · Theranostics · 2019

Why this rating

Evidence is primarily from animal models (mice/rats); human clinical data is limited in this review.

Source

Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics

Xiaojun Feng et al. · Theranostics · 2019

DOI 10.7150/thno.30787

narrative_reviewCited 430×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →